A group of 28 research firms covering Gilead Sciences gave shares of the company a consensus recommendation of 'Buy', Market Beat ratings reported. Gilead Sciences traded up 0.9201% on Monday, reaching $116.6636.

One analyst rated the company's stock as 'sell recommendation', four assigned a 'hold recommendation', and nineteen analysts issued a 'buy recommendation'. Three analysts have assigned a 'strong buy recommendation' to the company.

The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $127.33. The company's stock had a trading volume of 1,797,991 shares. It has a 52-week low of $85.95 and a 52-week high of $123.37.

The stock has a market cap of $171.22 billion and a price-to-earnings ratio of 12.3115. The firm's 50-day moving average price is $116.16 and its 200-day moving average price is $108.41.

The company last released its earnings results on July 28th. Gilead Sciences reported $3.15 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.32.

It earned revenue of $8.22 billion for the quarter as compared to the consensus estimate of $7.60 billion. Previous year during the same quarter, the company earned $2.36 earnings per share.

The firm's revenue for the quarter was up 25.8% on a year-over-year basis. On average, analysts expected that Gilead Sciences will post $11.66 earnings per share for the current year.

The firms even declared a quarterly dividend. The dividend will be paid on Tuesday, September 29th.